News

Under the terms of the agreement, Merck will obtain the rights to use the technology with two investigational antigen-specific cancer immunotherapies which are in pre-clinical development. PDS Biotechnology

Led by Edward Lin,a medical oncologist at the University of Washington and his collaborators, the study will be the first to specifically target colon cancer stem cells. The

The multicenter, multinational, partially randomized, open-label trial includes 120 to 140 previously treated subjects (PTP). The PROTECT VIII (PROphylaxis in hemophilia A patienTs via directly pEgylated long-aCTing rFVIII)

ADCs will be developed using CRT antibodies and peptides and ADCT’s ‘ warhead’ and linker chemistries. As part of the development programme, ADCT will grant funds for preclinical

The acquisition, which was initially announced on 10 April 2012, includes KAI’s main product KAI-4169, an agent being studied to treat secondary hyperparathyroidism in patients with chronic kidney

Amitiza is a prostone, a local activator of type-2 chloride ion channels (ClC-2) in cells lining the small intestine. In September 2010, a marketing application was submitted to

With the new acquisition, Renaissance has access to world-class semi-solid, liquid, and sterile pharmaceutical contract development and manufacturing capabilities of DPT Laboratories. Under the deal, the current shareholders

As part of the collaboration, Prosonix will work closely with Omar Usmani, an internationally recognised expert in respiratory diseases and inhaled drug delivery at the college’s National Heart

T2D is one of the most burdensome chronic non-communicable diseases, which is fast reaching epidemic proportions throughout the world. Under the terms of the license, SatRx has received